Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) shares traded down 5.4% during trading on Wednesday following insider selling activity. The stock traded as low as $19.80 and last traded at $21.04. 6,066,561 shares were traded during mid-day trading, a decline of 26% from the average session volume of 8,157,803 shares. The stock had previously closed at $22.24.
Specifically, insider Soleil Boughton sold 2,339 shares of the firm’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the completion of the transaction, the insider now owns 169,935 shares of the company’s stock, valued at $3,935,694.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Michael Chi sold 17,304 shares of the business’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $22.00, for a total value of $380,688.00. Following the completion of the sale, the insider now directly owns 193,980 shares in the company, valued at $4,267,560. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here.
Analysts Set New Price Targets
Several research firms have recently issued reports on HIMS. TD Cowen lifted their price target on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Needham & Company LLC started coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. Bank of America boosted their price objective on shares of Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Hims & Hers Health currently has an average rating of “Moderate Buy” and an average target price of $20.21.
Hims & Hers Health Price Performance
The company has a market capitalization of $4.09 billion, a P/E ratio of 252.63 and a beta of 1.06. The firm’s 50-day moving average is $17.84 and its 200-day moving average is $17.99.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The firm had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same quarter in the previous year, the firm posted ($0.03) EPS. The company’s revenue for the quarter was up 51.8% compared to the same quarter last year. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.
Institutional Trading of Hims & Hers Health
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in shares of Hims & Hers Health by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 14,173,285 shares of the company’s stock valued at $126,142,000 after acquiring an additional 46,541 shares during the period. State of Michigan Retirement System bought a new stake in shares of Hims & Hers Health during the 1st quarter valued at $2,785,000. Lake Street Private Wealth LLC bought a new stake in shares of Hims & Hers Health during the 1st quarter valued at $650,000. Principal Financial Group Inc. lifted its stake in shares of Hims & Hers Health by 17.9% during the 1st quarter. Principal Financial Group Inc. now owns 16,655 shares of the company’s stock valued at $258,000 after buying an additional 2,525 shares in the last quarter. Finally, Diversify Advisory Services LLC purchased a new stake in Hims & Hers Health in the 1st quarter worth $701,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.